Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

Core Viewpoint - Regeneron reported strong quarterly earnings of $12.89 per share, significantly exceeding the Zacks Consensus Estimate of $8.03 per share, marking an earnings surprise of +60.52% [1][2] Financial Performance - The company achieved revenues of $3.68 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 9.91% and showing an increase from $3.55 billion year-over-year [2] - Over the last four quarters, Regeneron has exceeded consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] Stock Performance - Regeneron shares have declined approximately 23.4% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] - The current Zacks Rank for Regeneron is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $9.18 on revenues of $3.53 billion, while the estimate for the current fiscal year is $35.73 on revenues of $13.67 billion [7] - The trend of estimate revisions prior to the earnings release was unfavorable, which may impact future stock performance [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Regeneron belongs, is currently in the top 40% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]